Gachon University Gil Medical Center

- Invited Neurophet’s scientific advisor Stephen Salloway , professor of Neurology at Brown Medical School as guest speaker - Shared latest insights on brain image analysis used for prescription of Alzheimer’s disease treatments such as ‘Leqembi’ and ‘Kisunla’ SEOUL, South Korea , Oct. 18, 2024 /PRNewswire/ -- Neurophet, an artificial intelligence (AI) solution company for brain disease, hosted Neurophet Symposium with Professor Stephen Salloway , a leading authority for the establishment of Alzheimer’s treatment guidelines in the U.S., to share the latest insights with domestic medical professionals. About 60 medical professionals from the departments of neurology, radiology, psychiatry, and nuclear medicine, related to the practical use of Alzheimer’s disease treatments, from across the country attended the event. This symposium was held at JW Marriott Hotel Seoul with the title “Alzheimer’s Treatment Era with Neurophet.” At the symposium, international medical professionals exchanged the latest opinions on brain image analysis technology related to the prescription and interpretation of Alzheimer’s disease treatments. Stephen Salloway , professor of Neurology at Brown University and Won-Jin Moon, professor of Radiology at Konkuk University Medical Center attended as speakers. Kee-Hyung Park , professor of Neurology at Gachon University Gil Medical Center and Hyun Kook Lim , professor of Psychiatry at The Catholic University of Korea Yeouido St. Mary’s Hospital also attended as chairs. Neurophet recently appointed Professor Stephen Salloway as scientific advisor. He is a professor of Neurology and Psychiatry at the Warren Alpert Medical School of Brown University . He also serves as the Founding Director of Memory and Aging Program at Butler Hospital in the U.S. Professor Salloway is a leading expert in the field of Alzheimer’s disease treatments, providing clinical guidelines for the prescription of anti-amyloid treatments. He is actively involved in research on anti-amyloid treatments, including comparative studies between donanemab and aducanumab. “This symposium was a valuable exchange between Professor Stephen Salloway , who presented the prescribing criteria for Alzheimer’s disease treatments and leading medical professionals in the field of Alzheimer’s treatment in Korea” said Jake Junkil Been, CEO of Neurophet. “Neurophet will continue to strengthen research and development related to Alzheimer’s disease treatment prescriptions, further enhancing its expertise in brain image analysis.” Last July, Neurophet launched ‘Neurophet AQUA AD’, the software for Alzheimer’s disease (AD) treatment prescription and monitoring treatment effects and side effects. This solution is currently preparing for medical device certifications in Korea, the U.S., and Japan . About Neurophet Neurophet has specialized in developing solutions for diagnosis support, treatment guides, and treatment devices targeting brain diseases based on cutting-edge artificial intelligence (AI) technology. The company was founded in 2016 by Jake Junkil Been, CEO, and Donghyeon Kim, CTO, who developed the next-generation neuro-navigation system. Major products include brain MRI analysis software “Neurophet AQUA”, brain PET image analysis (PET tracer deposition) software “Neurophet SCALE PET”, brain imaging treatment planning software for electric and magnetic brain stimulation “Neurophet tES/TMS LAB”. Neurophet has set its top priority to helping patients suffering from brain diseases. Based on expertise in neuroscience, Neurophet will continue to challenge and grow to explore the human brain’s health and pioneer solutions for brain diseases with AI technology. View original content to download multimedia: SOURCE Neurophet

SEOUL, South Korea, Nov. 16, 2023 /PRNewswire/ -- Heuron, a medical AI (artificial intelligence) imaging software solution company, under the leadership of CEO Dr. Donghoon Shin, is scheduled to take part in the 2023 Radiological Society of North America (RSNA) conference, scheduled for this month in Chicago, U.S. The company will showcase booth exhibitions and present research abstracts at the event. Continue Reading Heuron to Participate in RSNA 2023, Showcasing Neuro AI Solutions During this conference, Heuron will be showcasing Heuron AgingCare Suite™, an MRI-based diagnostic support solution for degenerative brain diseases, and Heuron StroCare Suite™, a non-contrast CT-based comprehensive diagnostic support solution for stroke. They will also feature Veuron-Brain-pAb3, which recently obtained certification (510(k) Clearance) from the U.S. FDA. In addition to introducing their products, Heuron will offer attendees the opportunity to experience product demonstrations and provide insights into how each product can enhance workflow, increase diagnostic accuracy, and improve reading efficiency. Moreover, during the research abstract presentation, Heuron will disclose the clinical evaluation results of Heuron ELVO, a component of Heuron StroCare Suite™, designed to identify patients with suspected emergent large vessel occlusions automatically. The current stroke diagnosis and treatment procedure typically starts with a non-contrast CT scan to rule out cerebral hemorrhage. If hemorrhage is not detected, a CT angiography may be conducted by the clinician to detect large vessel occlusion, then treatment decisions are made based on these results. However, if the possibility to identify patients in need of immediate intervention during the initial non-contrast CT scan without the requirement for CT angiography, it would significantly reduce the treatment time, leading to improved patient outcomes and survival rates. In this study, the accuracy of identifying patients with emergent large vessel occlusion based on non-contrast CT images was compared, both with and without reference to Heuron ELVO's analysis results. The study concluded that Heuron ELVO significantly enhances clinical efficacy by enabling physicians to make faster and more accurate diagnoses. Heuron's CEO, Dr. Donghoon Shin, stated, "Through this special gathering of medical imaging experts and industry professionals from around the world, we plan to introduce Heuron's innovative product lineup and our unique AI technology to the global market. We are committed to actively promoting the adoption of Heuron's AI solutions in the medical field across various countries." The Radiological Society of North America (RSNA) is the world's largest radiology organization, with approximately 50,000 members including healthcare professionals, manufacturers, distributors, and companies. In addition to the exhibition, there will be opportunities to share the latest trends, new technologies, and study results in the field of radiology. Heuron Co., Ltd. Heuron is a medical AI software company specializing in brain and neurological disorders, founded in 2017 by Professor Donghoon Shin of the Department of Neurology at Gachon University Gil Medical Center. Heuron provides diagnostic support AI software designed to automatically perform quantitative analyses on medical images of the brain, including MRI, PET, and CT, specifically for neurodegenerative conditions like Parkinson's disease, dementia, and strokes. This software aids healthcare professionals in making accurate and swift diagnoses. Heuron developed Korea's first dementia analysis software that obtained approval from the U.S. FDA and acquired European CE certification. SOURCE Heuron Co., Ltd.

GENOA, Italy, Nov. 17, 2022 /PRNewswire/ -- The world's first simultaneous multi-channel/multi-nuclear 11.74T MRI system is currently under development at Gachon University Gil Medical Center (GUGMC). Continue Reading In operation the most innovative 11.74T MRI Core Magnet to be used on humans The world’s first simultaneous multi-channel/multi-nuclear 11.74T MRI system is currently under development at Gachon University Gil Medical Center with ASG Superconductors The world’s first simultaneous multi-channel/multi-nuclear 11.74T MRI system is currently under development at Gachon University Gil Medical Center with ASG Superconductors In the first Half of 2022 GUGMC successfully completed the Site Acceptance Test of the Magnet, which is a core part of the brain-specific ultra-precision 11.74T MRI that is being jointly developed with ASG Superconductors (ASG) in Italy. GUGMC invited technical managers of ASG and experts from Korea for performance evaluation of the 11.74T MRI Magnet. Now one of the most sophisticated magnets in the world is "in operation" and fully serviced by ASG technicians onsite. At the same time the evaluation committee confirmed that the magnetic field reached the target field density while maintaining stability and uniformity. The Site Acceptance Test evaluated three main criteria: 1) the internal temperature of the 11.74T MRI magnet (< 2.2K (Kelvin)), 2) the intensity of the magnetic field (11.74T at 2.2K) 3) the uniformity of the magnetic field. The test satisfied these three criteria allowing the project to proceed to the next step. The researchers at GUGMC are aiming to operate the world's first simultaneous multi-channel/multi-nuclear 11.74T MRI system before the end of this year combining the 11.74T magnet with gradient magnetic coils, RF coil s , electronic equipment, power supplies, etc. Brain images acquired with the 11.74T MRI are expected to be almost 10 times more detailed than those obtained from a standard 1.5T MRI, providing researchers with ultra-high-resolution images of the brain structures for the early diagnosis and treatment of neuro-degenerative brain diseases such as Parkinson's disease, Alzheimer's disease and stroke, etc. Professor Woo-Kyung KIM, President of Gachon University Gil Medical Center (President of the Neuroscience Research Institute) said, "The ultra-high resolution brain images obtained from the 11.74T MRI system are expected to provide significant clues for the early diagnosis and treatment of neuro-degenerative brain diseases such as Parkinson's disease, Alzheimer's and stroke, etc. This 11.74T project (Principal Investigator: Prof. Jun-Young CHUNG) is supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry for Health and Welfare, Korea." Stefano Pittaluga Sales Manager UHF and MRI of ASG Superconductors said, "This is another important milestone for our superconducting technology track record in a very challenging and exclusive sector like Ultra High Field MRI magnets development. Furthermore, we're very proud to collaborate with such a prestigious institute as GUGMC and we're confident that in the coming years relevant improvements in healthcare will be achieved thanks to this very sophisticated MRI technology system magnet based on our cutting edge 11.74T magnet and GUGMC's scientific work" Video - Photo - Photo - Logo - SOURCE ASG Superconductors